Skip to main content
Industry News
Medtronic's MiniMed shows promise for reducing A1C in diabetes

Patients with type 1 diabetes who used the Medtronic MiniMed 670G, a hybrid closed-loop system, had their average A1C reduced by 0.9% from baseline to 6 months and by 1.2% from baseline to 12 months, according to findings presented at the American Association of Diabetes Educators annual meeting. Researchers surveyed 33 adults and found that participants also experienced time-in-range benefits and reported an average satisfaction score of 3.79 out of 5.

Full Story: